Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
04 nov. 2021 07h30 HE
|
Arbutus Biopharma Corporation
On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021 First patient dosed in Phase 2a clinical trial combining AB-729, Peg-IFNα-2a and nucleos(t)ide analog (“NA”) therapy ...
Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021
01 nov. 2021 16h05 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
21 oct. 2021 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus to Participate in October Investor Conferences
28 sept. 2021 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
21 sept. 2021 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus to Participate in Upcoming Investor Conferences
07 sept. 2021 08h00 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update
05 août 2021 07h30 HE
|
Arbutus Biopharma Corporation
New data on AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress™; all AB-729 abstracts selected for best of ILC™ ...
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
03 août 2021 08h00 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update
29 juil. 2021 08h00 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent
07 juil. 2021 07h00 HE
|
Arbutus Biopharma Corporation
Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic...